{"id":825653,"date":"2025-03-13T16:23:58","date_gmt":"2025-03-13T20:23:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/"},"modified":"2025-03-13T16:23:58","modified_gmt":"2025-03-13T20:23:58","slug":"exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/","title":{"rendered":"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia"},"content":{"rendered":"

<\/p>\n

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia<\/b><\/p>\n

CHICAGO–(BUSINESS WIRE<\/a>)–
\nExicure, Inc. (Nasdaq: XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses Thereof.”<\/i> This patent covers the company\u2019s innovative combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx.\n<\/p>\n

\nThe newly granted patent supports Exicure\u2019s ongoing Phase 2 clinical trial (NCT05561751), which evaluates the combination of GPC-100 and propranolol in multiple myeloma patients. This method aims to improve hematopoietic stem cell mobilization by co-targeting CXCR4 and ADRB2, thereby enhancing the efficacy of CXCR4 inhibitors like GPC-100.\n<\/p>\n

\n\u201cThis issuance reinforces the exclusivity of our lead clinical program,\u201d said Andy Yoo, CEO of Exicure, Inc. \u201cBy co-targeting CXCR4 and ADRB2, we can significantly enhance the potency of CXCR4 inhibitors like GPC-100. This opens new possibilities for these inhibitors to become more effective therapies, and our well-devised patent portfolio ensures strong intellectual property protection for this proprietary approach.\u201d\n<\/p>\n

\nThis patent family has already been granted in the United States, Japan, and Taiwan, with applications pending in other key jurisdictions.\n<\/p>\n

About Exicure, Inc.<\/b><\/p>\n

\nExicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. There can be no assurance regarding our ability to comply with the Panel\u2019s decision and the applicable listing criteria by the deadline or thereafter. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual outcomes to differ materially from the outcomes expressed or implied by this report. Such risks include, among others, the possibility we will not be able to cure existing listing deficiencies, the possibility of additional deficiencies, the risk that the Company may not adequately comply with the terms of the Panel\u2019s decision, and the risk that Nasdaq will ultimately delist the Company\u2019s common stock. All such factors are difficult to predict and may be beyond the Company\u2019s control. The Company undertakes no obligation and does not intend to update or revise any forward-looking statements contained herein, except as required by law or regulation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250313950375\/en\/<\/a><\/span><\/p>\n

Media Contact:
\n<\/b>
Sarah Ellinwood, PhD
\n
Kendall Investor Relations
\n
sellinwood@kendallir.com<\/a><\/p>\n

KEYWORDS:<\/b> Australia\/Oceania Australia United States North America Illinois<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia CHICAGO–(BUSINESS WIRE)– Exicure, Inc. (Nasdaq: XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses Thereof.” This patent covers the company\u2019s innovative combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx. The newly granted patent supports Exicure\u2019s ongoing Phase 2 clinical trial (NCT05561751), which evaluates the combination of GPC-100 and propranolol in multiple myeloma patients. This method aims to improve hematopoietic stem cell mobilization by co-targeting CXCR4 and ADRB2, thereby enhancing the efficacy of CXCR4 inhibitors like GPC-100. \u201cThis issuance reinforces the exclusivity of our lead clinical program,\u201d said Andy Yoo, CEO of Exicure, Inc. \u201cBy co-targeting CXCR4 and … <\/p>\n

Continue reading “Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-825653","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nExicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia CHICAGO–(BUSINESS WIRE)– Exicure, Inc. (Nasdaq: XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses Thereof.” This patent covers the company\u2019s innovative combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx. The newly granted patent supports Exicure\u2019s ongoing Phase 2 clinical trial (NCT05561751), which evaluates the combination of GPC-100 and propranolol in multiple myeloma patients. This method aims to improve hematopoietic stem cell mobilization by co-targeting CXCR4 and ADRB2, thereby enhancing the efficacy of CXCR4 inhibitors like GPC-100. \u201cThis issuance reinforces the exclusivity of our lead clinical program,\u201d said Andy Yoo, CEO of Exicure, Inc. \u201cBy co-targeting CXCR4 and … Continue reading "Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-13T20:23:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250313950375r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia\",\"datePublished\":\"2025-03-13T20:23:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/\"},\"wordCount\":493,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250313950375r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/\",\"name\":\"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250313950375r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-03-13T20:23:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250313950375r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250313950375r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/","og_locale":"en_US","og_type":"article","og_title":"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Market Newsdesk","og_description":"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia CHICAGO–(BUSINESS WIRE)– Exicure, Inc. (Nasdaq: XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses Thereof.” This patent covers the company\u2019s innovative combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx. The newly granted patent supports Exicure\u2019s ongoing Phase 2 clinical trial (NCT05561751), which evaluates the combination of GPC-100 and propranolol in multiple myeloma patients. This method aims to improve hematopoietic stem cell mobilization by co-targeting CXCR4 and ADRB2, thereby enhancing the efficacy of CXCR4 inhibitors like GPC-100. \u201cThis issuance reinforces the exclusivity of our lead clinical program,\u201d said Andy Yoo, CEO of Exicure, Inc. \u201cBy co-targeting CXCR4 and … Continue reading \"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-13T20:23:58+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250313950375r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia","datePublished":"2025-03-13T20:23:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/"},"wordCount":493,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250313950375r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/","name":"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250313950375r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-03-13T20:23:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250313950375r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250313950375r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/825653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=825653"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/825653\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=825653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=825653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=825653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}